Review
Benefits and risks of thrombolytic, anticoagulant and antiplatelet therapies in atrial fibrillation
Affiliations
- PMID: 8439785
Item in Clipboard
Review
Benefits and risks of thrombolytic, anticoagulant and antiplatelet therapies in atrial fibrillation
Br J Hosp Med.
1993 Feb.
Abstract
The decision whether to anticoagulate is a common dilemma when faced with a patient with atrial fibrillation. This article reviews the role of warfarin and antiplatelet agents and recommends a rational approach to the management of this condition.
Similar articles
-
[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].G Chir. 1995 Mar;16(3):137-9. G Chir. 1995. PMID: 7547128 Clinical Trial. Italian. No abstract available.
-
[Atrial fibrillation].Praxis (Bern 1994). 1996 Apr 30;85(18):600-3. Praxis (Bern 1994). 1996. PMID: 8701164 German.
-
[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy].Med Clin (Barc). 1996 Apr 20;106(15):586-9. Med Clin (Barc). 1996. PMID: 8656759 Review. Spanish. No abstract available.
-
Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation.Age Ageing. 2007 Mar;36(2):117-9. doi: 10.1093/ageing/afl181. Epub 2007 Jan 25. Age Ageing. 2007. PMID: 17255089 No abstract available.
-
Antithrombotic therapy in atrial fibrillation.Can Fam Physician. 1996 Jul;42:1341-5. Can Fam Physician. 1996. PMID: 8754703 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical